Description

This issue of Vital Signs, released on July 3, 2006, provides a strategic overview of the expanding role of in-vitro diagnostics with a special focus on molecular diagnostics and companion diagnostics. Additionally, an emerging company profile is provided on Target Discovery, an innovative personalized medicine company focused on the development of theranostic tests to guide treatment decisions. Reimbursement and regulatory news from the FDA and CMS are also provided for the week of June 21 - June 26, 2006.